Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug owned by Inforlife Sa. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 26, 2039. Details of Norepinephrine Bitartrate In 0.9% Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10888534 | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Norepinephrine Bitartrate In 0.9% Sodium Chloride's patents.
Latest Legal Activities on Norepinephrine Bitartrate In 0.9% Sodium Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Norepinephrine Bitartrate In 0.9% Sodium Chloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888534 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Aug, 2023 | US10568850 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Mar, 2023 | US10420735 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 14 Mar, 2023 | US11602508 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Mar, 2023 | US11602508 |
| Mail Post Card | 09 Mar, 2023 | US11602508 |
| Email Notification Critical | 01 Mar, 2023 | US11602508 |
| Email Notification Critical | 23 Feb, 2023 | US11602508 |
| Issue Notification Mailed Critical | 22 Feb, 2023 | US11602508 |
| Dispatch to FDC | 10 Feb, 2023 | US11602508 |
US patents provide insights into the exclusivity only within the United States, but Norepinephrine Bitartrate In 0.9% Sodium Chloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Norepinephrine Bitartrate In 0.9% Sodium Chloride's family patents as well as insights into ongoing legal events on those patents.
Norepinephrine Bitartrate In 0.9% Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Norepinephrine Bitartrate In 0.9% Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 26, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Norepinephrine Bitartrate In 0.9% Sodium Chloride Generic API suppliers:
Norepinephrine Bitartrate is the generic name for the brand Norepinephrine Bitartrate In 0.9% Sodium Chloride. 16 different companies have already filed for the generic of Norepinephrine Bitartrate In 0.9% Sodium Chloride, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Norepinephrine Bitartrate In 0.9% Sodium Chloride's generic
Alternative Brands for Norepinephrine Bitartrate In 0.9% Sodium Chloride
Norepinephrine Bitartrate In 0.9% Sodium Chloride which is used for increasing blood pressure in adult patients with severe, acute hypotension., has several other brand drugs using the same active ingredient (Norepinephrine Bitartrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Baxter Hlthcare Corp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride's active ingredient. Check the complete list of approved generic manufacturers for Norepinephrine Bitartrate In 0.9% Sodium Chloride
About Norepinephrine Bitartrate In 0.9% Sodium Chloride
Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug owned by Inforlife Sa. It is used for increasing blood pressure in adult patients with severe, acute hypotension. Norepinephrine Bitartrate In 0.9% Sodium Chloride uses Norepinephrine Bitartrate as an active ingredient. Norepinephrine Bitartrate In 0.9% Sodium Chloride was launched by Inforlife in 2022.
Approval Date:
Norepinephrine Bitartrate In 0.9% Sodium Chloride was approved by FDA for market use on 15 September, 2022.
Active Ingredient:
Norepinephrine Bitartrate In 0.9% Sodium Chloride uses Norepinephrine Bitartrate as the active ingredient. Check out other Drugs and Companies using Norepinephrine Bitartrate ingredient
Treatment:
Norepinephrine Bitartrate In 0.9% Sodium Chloride is used for increasing blood pressure in adult patients with severe, acute hypotension.
Dosage:
Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug owned by Long Grove Pharmaceuticals Llc. It is protected by 6 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2038. Details of Norepinephrine Bitartrate In 0.9% Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10420735 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
| US10226436 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
| US10568850 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
| US10159657 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
| US11602508 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
| US11413259 | Norepinephrine compositions and methods therefor |
Jan, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Norepinephrine Bitartrate In 0.9% Sodium Chloride's patents.
Latest Legal Activities on Norepinephrine Bitartrate In 0.9% Sodium Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Norepinephrine Bitartrate In 0.9% Sodium Chloride.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888534 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Aug, 2023 | US10568850 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Mar, 2023 | US10420735 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 14 Mar, 2023 | US11602508 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Mar, 2023 | US11602508 |
| Mail Post Card | 09 Mar, 2023 | US11602508 |
| Email Notification Critical | 01 Mar, 2023 | US11602508 |
| Email Notification Critical | 23 Feb, 2023 | US11602508 |
| Issue Notification Mailed Critical | 22 Feb, 2023 | US11602508 |
| Dispatch to FDC | 10 Feb, 2023 | US11602508 |
US patents provide insights into the exclusivity only within the United States, but Norepinephrine Bitartrate In 0.9% Sodium Chloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Norepinephrine Bitartrate In 0.9% Sodium Chloride's family patents as well as insights into ongoing legal events on those patents.
Norepinephrine Bitartrate In 0.9% Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Norepinephrine Bitartrate In 0.9% Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 30, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Norepinephrine Bitartrate In 0.9% Sodium Chloride Generic API suppliers:
Norepinephrine Bitartrate is the generic name for the brand Norepinephrine Bitartrate In 0.9% Sodium Chloride. 16 different companies have already filed for the generic of Norepinephrine Bitartrate In 0.9% Sodium Chloride, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Norepinephrine Bitartrate In 0.9% Sodium Chloride's generic
Alternative Brands for Norepinephrine Bitartrate In 0.9% Sodium Chloride
Norepinephrine Bitartrate In 0.9% Sodium Chloride which is used for increasing blood pressure in adult patients with severe, acute hypotension., has several other brand drugs using the same active ingredient (Norepinephrine Bitartrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Baxter Hlthcare Corp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride's active ingredient. Check the complete list of approved generic manufacturers for Norepinephrine Bitartrate In 0.9% Sodium Chloride
About Norepinephrine Bitartrate In 0.9% Sodium Chloride
Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug owned by Long Grove Pharmaceuticals Llc. It is used for increasing blood pressure in adult patients with severe, acute hypotension. Norepinephrine Bitartrate In 0.9% Sodium Chloride uses Norepinephrine Bitartrate as an active ingredient. Norepinephrine Bitartrate In 0.9% Sodium Chloride was launched by Long Grove Pharms in 2022.
Approval Date:
Norepinephrine Bitartrate In 0.9% Sodium Chloride was approved by FDA for market use on 06 October, 2022.
Active Ingredient:
Norepinephrine Bitartrate In 0.9% Sodium Chloride uses Norepinephrine Bitartrate as the active ingredient. Check out other Drugs and Companies using Norepinephrine Bitartrate ingredient
Treatment:
Norepinephrine Bitartrate In 0.9% Sodium Chloride is used for increasing blood pressure in adult patients with severe, acute hypotension.
Dosage:
Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |